Tag: filing

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).

CLAYMONT, Del., June 23, 2026 (GLOBE NEWSWIRE) -- Archimedes Tech SPAC Partners II Co. (Nasdaq: ATII), a publicly traded special purpose acquisition company (“ATII” or “Archimedes II”), today announced the filing with the U.S. Securities and Exchange Commission (the “SEC”), on June 22, 2026, of an amendment to the registration statement on Form S-4 (File No.: 333-295563) (as may be amended from time to time, the “Registration Statement”) previously filed in connection with the previously announced proposed business combination with Forge Nano, Inc. (“Forge Nano”). The Registration Statement includes a preliminary proxy statement/prospectus and has not yet been declared effective. The Registration Statement was filed by ATII Holdings Inc. (CIK 0002101833), ATII’s wholly-owned subsidiary (“Pubco”), and Forge Nano (CIK 0001719324) and is available free of charge at the SEC’s web site at www.sec.gov.

TORONTO, June 23, 2026 (GLOBE NEWSWIRE) -- Ninepoint Partners LP (“Ninepoint Partners”) today announced the estimated June 2026 cash distribution for the ETF Series of Ninepoint Cash Management Fund (the “Fund”). Ninepoint Partners expects to issue a press release on or about June 29, 2026, which will provide the final distribution rate. The record date for the cash distribution is June 30, 2026, payable on July 8, 2026.

NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the next steps in connection with changes to the Company’s share capital (the “Share Capital Amendment”).